Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Menopause

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,000 result(s) found for: Menopause. Displaying page 1 of 50.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-006082-32 Sponsor Protocol Number: 2293/2007 Start Date*: 2007-12-13
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: Female steroid hormones and protection from cardiovascular risk: staminal endothelial progenitor cells and menopause.
    Medical condition: Postmenopause
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051775 Postmenopause LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004246-41 Sponsor Protocol Number: RG_13-198 Start Date*: 2015-01-26
    Sponsor Name:Sandwell and West Birmingham Hospitals NHS Trust [...]
    1. Sandwell and West Birmingham Hospitals NHS Trust
    2. University of Birmingham
    Full Title: A phase III randomised study of folic acid supplementation in the management of menopausal symptoms in cancer survivors and healthy postmenopausal women
    Medical condition: Menopause Symptoms
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004872 10027311 Menopause flushing LLT
    18.0 10041244 - Social circumstances 10028812 Natural menopause LLT
    18.0 10041244 - Social circumstances 10027308 Menopause PT
    18.0 10041244 - Social circumstances 10051775 Postmenopause PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017144-14 Sponsor Protocol Number: 0903908 Start Date*: 2010-03-15
    Sponsor Name:Centre Hospitalier de Toulouse
    Full Title: Effets du traitement hormonal substitutif et du raloxifène sur les cellules dendritiques plasmacytoïdes et les lymphocytes B chez les femmes ménopausées
    Medical condition: Menopause
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027308 Menopause LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004427-19 Sponsor Protocol Number: 807 41 002 Start Date*: 2006-02-21
    Sponsor Name:Ludwig-Maximilians-Universitaet Muenchen
    Full Title: Health-related quality of life (QoL) and psychological well-being after withdrawal from hormone therapy (HT). A randomised double-blind placebo-controlled trial.
    Medical condition: Menopause and female climacteric states
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027308 Menopause LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000059-38 Sponsor Protocol Number: 21810 Start Date*: 2021-11-17
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women.
    Medical condition: Vasomotor symptoms associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10050903 Postmenopausal symptoms LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) FI (Completed) DK (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004855-34 Sponsor Protocol Number: 21652 Start Date*: 2021-11-25
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women
    Medical condition: Vasomotor symptoms associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10050903 Postmenopausal symptoms LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) NO (Completed) PT (Completed) SK (Completed) PL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004908-33 Sponsor Protocol Number: 21651 Start Date*: 2021-10-18
    Sponsor Name:Bayer Consumer Care AG
    Full Title: A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women
    Medical condition: Vasomotor symptoms associated with menopause
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038604 - Reproductive system and breast disorders 10050903 Postmenopausal symptoms LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) IT (Completed) HU (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-005109-23 Sponsor Protocol Number: AWC LowE Start Date*: 2009-08-05
    Sponsor Name:Uppsala University Hospital
    Full Title: Low-Dose Hormone Therapy Initiated early after Menopause and Changes in Artery Wall Composition (AWC), as Assesssed by High-Frequency Ultrasound.
    Medical condition: Age/menopause related changes in the artery wall composition after menopause
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    9.1 10051775 Postmenopause LLT
    9.1 10020388 Hormone replacement therapy LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005666-37 Sponsor Protocol Number: PrefoDIP Start Date*: 2012-10-17
    Sponsor Name:ZAMBON ITALIA
    Full Title: Evaluation of the effect exerted by 5-methyltetrahydrofolate (5-MTHF) and folic acid in postmenopausal women
    Medical condition: The study evaluates the effects of different forms of folates on cardiovascular risk factors in postmenopausal patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10041244 - Social circumstances 10051775 Postmenopause PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006053-41 Sponsor Protocol Number: MEFA 2008 Start Date*: 2009-05-19
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Estrogeni, fitoestrogeni o agopuntura nella terapia dei sintomi della menopausa fisiologica (versione del 18/9/2008 modificata in data 25/2/2009 in seguito ai chiarimenti richiesti dal CE Coordinat...
    Medical condition: Menopausa fisiologica
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028812 Natural menopause LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2023-000224-10 Sponsor Protocol Number: PBKV.5zdnia03.08.2022 Start Date*: 2023-08-17
    Sponsor Name:The Pharmaceutical Company LEK-AM Sp. Zo.o.
    Full Title: A randomized, double-blind, placebo-controlled, multicentre study to evaluate the effect of a 12-week dose of 35 mg DHEA on quality of life in menopausal women.
    Medical condition: Menopause
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000275-16 Sponsor Protocol Number: 2693-CL-0304 Start Date*: 2019-09-03
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Randomized, Placebo-controlled, Double-blind Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women Suffering from Vasomotor Symptoms (Hot Flashes) Associated with Me...
    Medical condition: Vasomotor Symptoms (Hot Flashes) Associated with Menopause
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004866 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) LV (Completed) ES (Completed) CZ (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001685-38 Sponsor Protocol Number: 2693-CL-0312 Start Date*: 2021-11-24
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women Suffering from Moderate to Severe Vasomotor Symptoms (H...
    Medical condition: Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004866 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) ES (Ongoing) IT (Completed) HU (Completed) FI (Completed) NL (Completed) NO (Completed) DE (Completed) PL (Completed) DK (Completed) BE (Completed) SK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001254-41 Sponsor Protocol Number: D3190C00013 Start Date*: 2008-06-25
    Sponsor Name:AstraZeneca AB
    Full Title: A single-centre, single-blind, randomised, placebo-controlled phase IIa study to investigate the effect of AZD1305 given as an iv infusion on left ventricular performance in patients with left vent...
    Medical condition: Left ventricular function in patient with left ventricular dysfunction.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2022-004160-16 Sponsor Protocol Number: PBKV.8zdnia01.06.2022 Start Date*: 2024-02-22
    Sponsor Name:The Pharmaceutical Company LEK-AM Sp. Zoo.
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study evaluating the effect of a 12-week DHEA combination of 20 mg and 2 mg prolonged-release melatonin on sleep quality an...
    Medical condition: Menopause, sleep disorders in the postmenopausal period
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003529-27 Sponsor Protocol Number: 2693-CL-0302 Start Date*: 2019-10-03
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Non- Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering...
    Medical condition: Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004866 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) LV (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-002094-22 Sponsor Protocol Number: 2013MM002B Start Date*: 2013-08-29
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust (RB&HFT)
    Full Title: Comparison of ultra-low-dose Oral versus Transdermal Hormone Therapy on coagulation activation and metabolic risk factors for Cardiovascular Disease
    Medical condition: The effect of oestrogen replacement therapy taken either orally or transdermally and observing any likely benefit of both these therapies on the risks Venous thromobembolic events and cardiovascul...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038604 - Reproductive system and breast disorders 10027309 Menopause and related conditions HLGT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003528-35 Sponsor Protocol Number: 2693-CL-0301 Start Date*: 2019-11-22
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering ...
    Medical condition: Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated with Menopause
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004866 10020407 Hot flashes LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-006943-29 Sponsor Protocol Number: 2006.453/46 Start Date*: 2009-01-07
    Sponsor Name:Hospices Civils de Lyon
    Full Title: ESSAI RANDOMISE, EN DOUBLE AVEUGLE CONTRE PLACEBO EVALUANT L’EFFICACITE DU RISEDRONATE ORAL 35 MG PAR SEMAINE DANS LA PREVENTION DE LA PERTE OSSEUSE CHEZ LA FEMME ATTEINTE D’UN CANCER DU SEIN TRAIT...
    Medical condition: Cancer du sein
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    9.1 10027308 Menopause LLT
    9.1 10049088 Osteopenia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003230-15 Sponsor Protocol Number: BEV-EFF Start Date*: 2006-10-17
    Sponsor Name:University Clinic Internal Medicine I
    Full Title: Phase I/II study investigating increasing doses of bevacizumab in patients with malignant effusion
    Medical condition: Malignant effusion in cancer patients requiring frequent centesis, at least two within six weeks
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 06:58:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA